Article Text

Download PDFPDF

Protocol
Role of the intelligent exercise rehabilitation management system on adherence of cardiac rehabilitation in patients with coronary heart disease: a randomised controlled crossover study protocol
  1. Linqi Xu1,
  2. Wenji Xiong2,
  3. Jinwei Li1,
  4. Hongyu Shi1,
  5. Meidi Shen1,
  6. Xin Zhang1,
  7. Yue Pang1,
  8. Yuanyuan Ni1,
  9. Wei Zhang1,
  10. Yuewei Li1,
  11. Lirong Guo1,
  12. Shuang Zhang1,
  13. Lijing Zhao1,
  14. Feng Li1
  1. 1School of Nursing, Jilin University, Changchun, Jilin, China
  2. 2The First Hospital of Jilin University, Changchun, Jilin, China
  1. Correspondence to Dr Feng Li; lifeng2912{at}163.com

Abstract

Introduction The benefits of cardiac rehabilitation (CR) on the reduction of cardiac and all-cause mortality are well documented. However, adherence remains suboptimal in China. It is clear that traditional CR does not meet the needs of many eligible patients and innovation is required to improve its application. Home-based CR (HBCR) is a cost-effective method that may be a valuable alternative for many individuals in China. In HBCR, it is often difficult to maintain an exercise intensity that is both effective and within safe limits, factors that are essential for patient safety. Mobile health interventions have the potential to overcome these obstacles and may be efficacious in improving adherence. The purpose of this study is to evaluate whether an Intelligent Exercise Rehabilitation Management System (IERMS)-based HBCR could improve adherence to CR and to assess the effects on exercise capacity, mental health, self-efficacy, quality of life and lifestyle-related risk factors.

Methods and analysis We propose a single-blinded, two-arm, randomised controlled crossover study of 70 patients with coronary heart disease (CHD). Participants will be randomly assigned in a 1:1 ratio to one of the two groups. Patients in group 1 will receive the IERMS intervention together with usual care for the first 6 weeks and usual care for the last 6 weeks, while patients assigned to group 2 will receive usual care for the first 6 weeks and will use IERMS in the last 6 weeks. The primary outcome is adherence to the programme and secondary outcomes include exercise capacity, psychological well-being, quality of life, self-efficacy and lifestyle-related risk factors. All secondary outcomes will be measured at baseline, 6 weeks and 12 weeks.

Ethics and dissemination This study has been approved by the Human Research Ethics Committee of the School of Nursing, Jilin University (HREC 2019120901). The results will be published in peer-reviewed journals and at conferences.

Trial registration number ChiCTR1900028182; Pre-results.

  • coronary heart disease
  • rehabilitation medicine
  • information technology
http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors LX and FL conceived the original concept of the study and wrote the first draft of the protocol manuscript. WX, JL, HS, MS, XZ, YP, YN, WZ, YL, LG, SZ and LZ contributed to the design of the study. LX, FL, JL, MS and XZ revised the manuscript. All authors read and approved the final manuscript.

  • Funding This work is financially supported by a Norman Bethune Plan Research Programme Grant from Jilin University (Study code: 2018A04) awarded to Dr Feng Li. Heart rate monitors are provided by Qingdao Magene Intelligent Technology Co., Ltd, China. The funding source does not influence or comment on planned methods, protocol, data analysis or the draft report.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement For patient confidentiality concerns and the access possibilities of the data source, the clinical data collected will not be shared with the public. However, non-clinical data, such as educational materials, will be shared with the public and other researchers.